Business, energy, technology, markets and global industry news from Business News Today

NT-proBNP

PharmaDeviceNews NT-proBNP
Representative image: A surgical team prepares a preserved donor heart in a high-tech transplant setting, reflecting the clinical and regulatory stakes behind United Therapeutics Corporation’s FDA-cleared UHeart xenotransplantation trial for end-stage heart failure.
Medical Devices & Diagnostics

Acarix beat NT-proBNP on false positives, but can its acoustic heart test survive external validation?

Acarix heart failure algorithms showed strong sensitivity and fewer false positives than NT-proBNP, but larger external validation is still required.

Read More
Pharma & Biotech

Gossamer Bio Phase 3 PROSERA results: what seralutinib’s near miss means for pulmonary arterial hypertension

Gossamer Bio’s Phase 3 PROSERA data for seralutinib in PAH missed its primary endpoint. Read what this means for regulators and clinicians.

Read More